



Jazz Pharmaceuticals Announces Pricing of Public Offering of Common Stock

May 11, 2010

PALO ALTO, Calif., May 11, 2010 /PRNewswire via COMTEX/ --Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today the pricing of its previously announced public offering of 7,000,000 shares of its common stock at a price to the public of \$8.35 per share. All of the shares in the offering are to be sold by Jazz Pharmaceuticals. The offering is expected to settle and close on May 14, 2010, subject to customary closing conditions. Barclays Capital Inc. is the sole book-running manager of the offering. Jazz Pharmaceuticals intends to use all of the net proceeds from the offering to repay a portion of its outstanding senior secured notes.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state in which such offer, solicitation or sale is not permitted. Copies of the final prospectus supplement and accompanying prospectus may be obtained when available from: Barclays Capital Inc., c/o Broadridge, Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, New York 11717; Barclaysprospectus@broadridge.com (phone: 888-603-5847).

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the completion of the public offering. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties related to completion of the public offering. There can be no assurance that Jazz Pharmaceuticals will be able to complete the public offering. Additional risks and uncertainties relating to the public offering, Jazz Pharmaceuticals and its business can be found under the heading "Risk Factors" in Jazz Pharmaceuticals' Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, filed with the Securities and Exchange Commission (SEC) on May 6, 2010, and in the final prospectus supplement related to the public offering to be filed with the SEC. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

SOURCE Jazz Pharmaceuticals, Inc.